Thu, Oct 30, 2014, 8:46 AM EDT - U.S. Markets open in 44 mins.

Recent

% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • purplehaze656 purplehaze656 Sep 5, 2013 2:15 PM Flag

    reality2

    In all likelihood, the Afrezza NDA will be approved by the FDA. Whether patients, physicians and payers will support it remains to be seen. But R&D on Afrezza is far from over. While inhaled insulin appears safe for short term use, the FDA will have concerns about the cumulative effect of delivering a growth hormone like insulin to the lung. It is likely that the FDA will require a number of post-marketing studies on Afrezza to support its long-tem use. When the FDA approved Pfizer’s Exubera, it did so on the condition of extensive continuing clinical trials to understand the effects of insulin on the lung. As part of the FDA’s Exubera approval, Pfizer was required to run a number of studies including:

    1) A five year large trial in 5,000 diabetics with Type 1 or Type 2 diabetes with 1:1 randomization to either Exubera or usual care. The objectives of this trial were to estimate the relative risk for developing clinically significant decline in lung function as well as the potential clinical risk associated with increases in insulin antibody formation on the potential for developing allergic and immune disorders;

    2) A long-term outpatient, open-label, parallel-group comparative trial of the efficacy and safety with Exubera compared with injected insulin therapy in adult Type 1 diabetes over 5 continuous years and 7 cumulative years of Exubera exposure.

    3) A long-term, outpatient , open-label, parallel-group comparative trial of the safety and efficacy of Exubera compared with injected insulin in adult Type 2 diabetes over 5 continuous years and 7 cumulative years of Exubera exposure.

    In addition, one year studies in Type 1 and Type 2 diabetes patient with asthma and COPD were also required. While one can never predict how the FDA will behave, it is hard to believe that Afrezza won’t be subjected to a similar post-marketing plan.

    These types of studies require a great deal of resources costing hundreds of millions of dollars. For a drug with th

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MNKD
6.07-0.11(-1.86%)Oct 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avon Products Inc.
NYSEWed, Oct 29, 2014 4:00 PM EDT
Novavax, Inc.
NasdaqGSWed, Oct 29, 2014 4:00 PM EDT